ValuEngine Lowers Simulations Plus (NASDAQ:SLP) to Buy

Simulations Plus (NASDAQ:SLP) was downgraded by research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research note issued on Friday, ValuEngine reports.

SLP has been the topic of a number of other research reports. Zacks Investment Research raised Simulations Plus from a “hold” rating to a “strong-buy” rating and set a $37.00 price target on the stock in a research note on Friday, July 19th. BidaskClub raised Simulations Plus from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 15th.

Shares of SLP stock traded down $4.96 during trading hours on Friday, reaching $36.79. The company had a trading volume of 564,583 shares, compared to its average volume of 81,053. The firm’s 50 day simple moving average is $31.63. The firm has a market capitalization of $644.97 million, a price-to-earnings ratio of 73.58 and a beta of -0.38. Simulations Plus has a 1-year low of $17.18 and a 1-year high of $41.95.

Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Wednesday, July 10th. The technology company reported $0.16 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.14 by $0.02. The company had revenue of $9.94 million for the quarter, compared to the consensus estimate of $9.85 million. Simulations Plus had a return on equity of 23.48% and a net margin of 24.09%. As a group, equities analysts expect that Simulations Plus will post 0.46 EPS for the current year.

In related news, Director Walter S. Woltosz sold 18,500 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $25.67, for a total transaction of $474,895.00. Following the sale, the director now owns 5,178,083 shares of the company’s stock, valued at approximately $132,921,390.61. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 31.57% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wasatch Advisors Inc. raised its stake in shares of Simulations Plus by 15.6% in the 1st quarter. Wasatch Advisors Inc. now owns 343,122 shares of the technology company’s stock valued at $7,243,000 after purchasing an additional 46,310 shares during the period. William Blair Investment Management LLC raised its stake in shares of Simulations Plus by 8.8% in the 1st quarter. William Blair Investment Management LLC now owns 485,040 shares of the technology company’s stock valued at $10,239,000 after purchasing an additional 39,114 shares during the period. Geode Capital Management LLC raised its stake in shares of Simulations Plus by 6.5% in the 4th quarter. Geode Capital Management LLC now owns 128,181 shares of the technology company’s stock valued at $2,550,000 after purchasing an additional 7,794 shares during the period. Crawford Investment Counsel Inc. raised its stake in shares of Simulations Plus by 6.0% in the 1st quarter. Crawford Investment Counsel Inc. now owns 355,057 shares of the technology company’s stock valued at $7,495,000 after purchasing an additional 20,009 shares during the period. Finally, Wedge Capital Management L L P NC raised its stake in shares of Simulations Plus by 16.5% in the 1st quarter. Wedge Capital Management L L P NC now owns 51,311 shares of the technology company’s stock valued at $1,083,000 after purchasing an additional 7,265 shares during the period. 41.26% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Further Reading: How to invest in blue-chip stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.